Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GRK2 | P25098 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16856782 | 0.84 | GAA (0.40) | ALDH1A1TDP1MEN1KMT2ANPSR1 | |
| SCHEMBL6920756 | 0.84 | MEN1 (0.38) | ALDH1A1TDP1MEN1KMT2ANPSR1 | |
| SCHEMBL12478993 | 0.84 | MEN1 (0.38) | ALDH1A1TDP1MEN1KMT2ANPSR1 | |
| SCHEMBL1563913 | 0.84 | ALDH1A1 (0.38) | ALDH1A1TDP1MEN1KMT2ANPSR1 | |
| SCHEMBL16046033 | 0.84 | ERN1 (0.39) | ALDH1A1TDP1MEN1KMT2AGRK2 | |
| SCHEMBL23641389 | 0.84 | MEN1 (0.38) | ALDH1A1TDP1MEN1KMT2ANPSR1 | |
| SCHEMBL7613538 | 0.83 | MAPT (0.40) | ALDH1A1TDP1MEN1KMT2ANPSR1 | |
| SCHEMBL31526382 | 0.80 | MEN1 (0.45) | ALDH1A1TDP1MEN1KMT2AGRK2 | |
| SCHEMBL8142077 | 0.79 | MEN1 (0.35) | ALDH1A1TDP1MEN1KMT2AGRK2 | |
| SCHEMBL18995848 | 0.79 | MEN1 (0.34) | ALDH1A1TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119865979-A | High-weldability circuit board surface treatment liquid and preparation method thereof | 深圳市华京超导材料有限公司 | 2025-04-22 | — | — | CN | claimed |
| US-20260136833-A1 | OPTOELECTRONIC COMPONENT WITH A PHOTOACTIVE LAYER DESIGNED AS A PLANAR HETEROJUNCTION | HELIATEK GMBH (DE) | 2026-05-14 | — | — | US | disclosed |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-12358903-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-120058674-A | 4 (1H-pyrazol-3-yl) piperidinyl derivative, preparation method thereof and application thereof in preparation of MNK inhibitor | 烟台新药创制山东省实验室 | 2025-05-30 | — | — | CN | disclosed |
| EP-4547670-A1 | POLYMORPHIC COMPOUNDS AND USES THEREOF | Tyra Biosciences, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4548730-A1 | OPTOELECTRONIC COMPONENT WITH A PHOTOACTIVE LAYER DESIGNED AS A PLANAR HETEROJUNCTION | Heliatek GmbH (DE) | 2025-05-07 | — | — | EP | disclosed |
| CN-119865979-A | High-weldability circuit board surface treatment liquid and preparation method thereof | 深圳市华京超导材料有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119865979-A | High-weldability circuit board surface treatment liquid and preparation method thereof | 深圳市华京超导材料有限公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-0882714-A1 | SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SS Pharmaceutical Co., Ltd. (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5840724-A | COMPOUNDS FOR TUMOR NECROSIS FACTOR OR ENZYME INHIBITORS OF PHOSPHODIESTERASES | RHONE-POULENC RORER LIMITED (GB) | 1998-11-24 | — | — | US | disclosed |
| WO-1998045294-A1 | COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-15 | — | — | WO | disclosed |
| EP-0741707-B1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE POULENC RORER LTD (GB) | 1998-04-01 | — | — | EP | disclosed |
| US-5698711-A | INHIBITORS OF TUMOR NECROSIS FACTOR, CYCLIC ADENOSINE-3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE AND EOSINOPHILS | RHONE-POULENC RORER LIMITED (GB) | 1997-12-16 | — | — | US | disclosed |
| US-5679696-A | FOR INHIBITING TUMOR NECROSIS FACTOR; ENZYME INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1997-10-21 | — | — | US | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358903-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | ALDH1A1 3805/4885TDP1 4671/4885MEN1 4302/4885 |
| US-20260136833-A1 | OPTOELECTRONIC COMPONENT WITH A PHOTOACTIVE LAYER DESIGNED AS A PLANAR HETEROJUNCTION | HCN2, HCN3, HCN4 | ALDH1A1 2078/4885TDP1 4620/4885MEN1 1422/4885 |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | ALDH1A1 2984/4885TDP1 4672/4885MEN1 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.